Investigating Variations in E. Coli Post in Vivo Gut Colonization Model

Overview

Pathogenic E. coli, particularly the globally prevalent sequence type 131 (ST131), poses a significant health threat, causing numerous infections annually. ST131 is an extended spectrum β-lactamase (ESBL) producing E. coli, exhibiting multidrug resistance. A clinical ESBL isolate, 1031, obtained from the CDC & FDA Antibiotic Resistance Isolate Bank, was examined in a mouse-based gut colonization model to assess new treatment effectiveness. Two distinct colonies, 1031-P and 1031-W, emerged post-challenge, indicating adaptation of the parent ST131 strain to the host environment. Various methods, including API20E tests, antibiotic sensitivity assays, and whole genome sequencing, using both Illumina sequencing short reads and Oxford Nanopore Technologies long reads to construct a full genome, were employed to analyze genetic differences. Results revealed mutations in transcription factors linked to antibiotic resistance and biofilm formation in 1031-W and 1031-P, along with increased antibiotic resistance compared to 1031. Understanding these mutations aids in targeting strains and mutations proactively in drug development, contributing to staying ahead of the pathogen and enhancing treatment strategies for ESBL E. coli. This research provides valuable insights into the impact of current treatments and ways to optimize drug development for combating ESBL E. coli effectively.

Competition history

• AJAS 2025 Category not listed

Related projects

Closest projects by meaning, across every fair and year in the corpus.

Browse more like this

• All Microbiology projects
• AJAS Microbiology projects
• Every AJAS 2025 project